The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
about
Colorectal cancer tumour markers and biomarkers: Recent therapeutic advancesClinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancerP53 mutations in colorectal cancer - molecular pathogenesis and pharmacological reactivationTransitions at CpG dinucleotides, geographic clustering of TP53 mutations and food availability patterns in colorectal cancerExpression of TIP-1 confers radioresistance of malignant glioma cellsRegulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11.Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy.Where now for anti-EGF receptor therapies in colorectal cancer?Inter-relationship between microsatellite instability, thymidylate synthase expression, and p53 status in colorectal cancer: implications for chemoresistanceAn explorative analysis of ERCC1-19q13 copy number aberrations in a chemonaive stage III colorectal cancer cohortClinical outcomes and correlates of TP53 mutations and cancer.Hierarchical clustering analysis of pathologic and molecular data identifies prognostically and biologically distinct groups of colorectal carcinomas.Survival of distinct Asian groups among colorectal cancer cases in CaliforniaPrognostic and predictive significance of MSI in stages II/III colon cancer.DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset.Quantitative expression analysis and prognostic significance of L-DOPA decarboxylase in colorectal adenocarcinoma.High expression of testes-specific protease 50 is associated with poor prognosis in colorectal carcinoma.Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803Increased expression of prothymosin-α, independently or combined with TP53, correlates with poor prognosis in colorectal cancerLIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers.The chromosomal instability pathway in colon cancerThe impact of chemotherapy-associated neutrophil/ lymphocyte counts on prognosis of adjuvant chemotherapy in colorectal cancerGenetics, cytogenetics, and epigenetics of colorectal cancer.Tissue microarray cytometry reveals positive impact of homeodomain interacting protein kinase 2 in colon cancer survival irrespective of p53 functionTP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cellsMolecular Prognostic and Predictive Markers in Colorectal Cancer: Current StatusRadiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition.Molecular diagnosis of response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer.Colorectal cancer in iran: molecular epidemiology and screening strategies.Mutational analysis and clinical correlation of metastatic colorectal cancer.PIK3CA mutations predict recurrence in localized microsatellite stable colon cancerMethylation of MGMT and ADAMTS14 in normal colon mucosa: biomarkers of a field defect for cancerization preferentially targeting elder African-Americans.Distinct pattern of mutations of conserved regions of TP53 in colorectal cancer patients in the Kashmir population: an emerging high-risk area.Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery.Evidence of linkage to chromosomes 10p15.3-p15.1, 14q24.3-q31.1 and 9q33.3-q34.3 in non-syndromic colorectal cancer families.Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?Radiation/paclitaxel treatment of p53-abnormal non-small cell lung cancer xenograft tumor and associated mechanism.TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer PatientsWild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancerRight-sided colon cancer and left-sided colorectal cancers respond differently to cetuximab.
P2860
Q26768427-5E629045-A0D6-458E-99EF-DA947E3385D3Q27002356-008770DC-1060-4B22-B66E-4B97F945C484Q27021759-6A9F8B23-C184-4147-85E2-1DFC986A2413Q27342770-D2A74A64-FC2B-4DC0-A457-46299EDC4FDCQ28483802-330C365B-9AB7-45BD-87E4-DF2036447CD9Q29976922-BDAEF589-A399-47E8-BB0C-D0E357A42EE5Q30939321-ACAA6D18-499E-4191-A32B-E5581BF8F70FQ31038305-D81D0797-4893-4811-B7B9-3F2780FCF5AAQ33245747-18378E0E-9B6A-41A0-93C7-EC6B855F41C2Q33589368-B7268EF1-BAB2-47FB-9D6B-09BCB292D1D5Q33693838-64FC7BD4-8C3B-4B99-A4D7-8F15E44615F3Q33695841-AA214CB6-DFC0-4DF6-AB4A-01C7067DB53FQ33703793-AA98119B-F375-42DD-8E04-98A9AD681EA3Q33735239-376963DE-9A90-4093-BBBD-901108D264A4Q33754380-B4F37A5C-59B3-4F98-86B0-D7F4C31AB7F3Q33834425-4C3C74C1-E77E-47F7-9EEA-A0862EBBFF79Q33963953-01CB1235-48F8-4208-B5DC-C5A3A7108F87Q34004105-F4AA33B1-D88D-48B5-8C00-C6FB9DF42E87Q34121399-FF5DFF5D-834F-4F7F-A639-25B6E27D2742Q34372540-B19305EB-0A1F-4AA3-9112-D867FDB34358Q34570062-3043F3B6-167D-4E2B-9923-BCFFCE1D9EDCQ34646737-3FD8F014-2CB2-46B1-967A-EB4E9C73E4AEQ34758641-6C02154E-2D57-4FD6-8C7C-DB3F6D9F6F07Q34838208-8FC75C7D-A33D-4587-920D-B0D730F61DDBQ34926012-28041381-A22B-4A88-BEF9-AA3FEE0C1C3BQ34976621-5C4345AF-FAD2-46F4-BE6F-D4159D49199AQ35005604-0D42C2CF-A8A9-4AD7-9229-E6875133C5D2Q35013576-7B2A6739-35F0-4D52-B44E-FF7C7435E174Q35034089-68EC59DA-9426-442E-A436-FF65ED8FE992Q35082873-D596F94E-7363-49C0-A4F4-22B36BF663EEQ35236785-FB83AE34-9931-468F-AEBA-E0C0A23DEC0EQ35550260-44BEFDEB-2C79-4191-AF9E-68797DA1168FQ35572900-599390B5-3EF4-462B-A3AA-88D580EBAEF5Q35583987-96E5DE39-0A08-4C3B-9578-32B987AAB880Q35603671-1C59216F-066E-4F44-A5E5-E2BD59DA2DF0Q35816829-AD635A97-8017-4C4D-82C6-F78004117FD9Q35964863-1B291BF1-32ED-49DA-95E0-C4C792D838D3Q36038603-82DC04A3-42B9-4AFC-BAAD-534984B91230Q36081402-F7C0B099-9C69-415F-9E3F-5E583ABF926AQ36121090-C7596A41-43CE-4484-8903-144CE057A1EA
P2860
The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The TP53 colorectal cancer int ...... ation, and adjuvant treatment.
@ast
The TP53 colorectal cancer int ...... ation, and adjuvant treatment.
@en
The TP53 colorectal cancer int ...... ation, and adjuvant treatment.
@nl
type
label
The TP53 colorectal cancer int ...... ation, and adjuvant treatment.
@ast
The TP53 colorectal cancer int ...... ation, and adjuvant treatment.
@en
The TP53 colorectal cancer int ...... ation, and adjuvant treatment.
@nl
prefLabel
The TP53 colorectal cancer int ...... ation, and adjuvant treatment.
@ast
The TP53 colorectal cancer int ...... ation, and adjuvant treatment.
@en
The TP53 colorectal cancer int ...... ation, and adjuvant treatment.
@nl
P2093
P356
P1476
The TP53 colorectal cancer int ...... ation, and adjuvant treatment.
@en
P2093
Antonio Russo
Barry Iacopetta
David Kerr
Nicola Gebbia
TP53-CRC Collaborative Study Group
Viviana Bazan
P304
P356
10.1200/JCO.2005.00.471
P407
P577
2005-09-19T00:00:00Z